| Reference |
|---|
Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87:211-9 pubmed publisher |
Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, et al. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC). Appl Immunohistochem Mol Morphol. 2015;23:60-70 pubmed publisher |
Doble B, Tan M, Harris A, Lorgelly P. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Rev Mol Diagn. 2015;15:235-54 pubmed publisher |
Zhang K, Deng H, Cagle P. Utility of immunohistochemistry in the diagnosis of pleuropulmonary and mediastinal cancers: a review and update. Arch Pathol Lab Med. 2014;138:1611-28 pubmed publisher |
Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, et al. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol. 2014;9:1470-6 pubmed publisher |
Cha Y, Lee J, Kim H, Lim S, Cho B, Lee C, et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS ONE. 2014;9:e103333 pubmed publisher |
Yang L, Li G, Zhao L, Pan F, Qiang J, Han S. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. Tumour Biol. 2014;35:9759-67 pubmed publisher |
Berghoff A, Birner P, Streubel B, Kenner L, Preusser M. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. APMIS. 2014;122:867-72 pubmed publisher |
Minca E, Lanigan C, Reynolds J, Wang Z, Ma P, Cicenia J, et al. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol. 2014;9:464-8 pubmed publisher |
Feng Y, Minca E, Lanigan C, Liu A, Zhang W, Yin L, et al. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. J Thorac Oncol. 2014;9:646-53 pubmed publisher |
Yang J, Zhang X, Su J, Xu C, Zhou Q, Tian H, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014;20:1383-92 pubmed publisher |
Shan L, Lian F, Guo L, Yang X, Ying J, Lin D. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement. Diagn Pathol. 2014;9:3 pubmed publisher |
Han X, Zhang N, Ma L, Lin D, Hao X, Liu Y, et al. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch. 2013;463:583-91 pubmed publisher |
Li Y, Pan Y, Wang R, Sun Y, Hu H, Shen X, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS ONE. 2013;8:e69016 pubmed publisher |
Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013;24:2589-93 pubmed publisher |
Niu H, Zhou Q, Wang F, Shao Q, Guan Y, Wen X, et al. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell Melanoma Res. 2013;26:646-53 pubmed publisher |
Selinger C, Rogers T, Russell P, O Toole S, Yip P, Wright G, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545-53 pubmed publisher |
Zhang Y, Jin M, Li L, Zhao H, Zeng X, Jiang L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues. PLoS ONE. 2013;8:e64821 pubmed publisher |
Roberts P. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics. 2013;7:91-101 pubmed publisher |
Nakamura H, Tsuta K, Yoshida A, Shibata T, Wakai S, Asamura H, et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol. 2013;66:705-7 pubmed publisher |
Filtenborg Barnkob B, Bzorek M. Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. Hum Pathol. 2013;44:1656-64 pubmed publisher |
Minca E, Portier B, Wang Z, Lanigan C, Farver C, Feng Y, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15:341-6 pubmed publisher |
Preusser M, Berghoff A, Ilhan Mutlu A, Magerle M, Dinhof C, Widhalm G, et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer. 2013;80:278-83 pubmed publisher |
Conklin C, Craddock K, Have C, Laskin J, Couture C, Ionescu D. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51 pubmed publisher |
Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, et al. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology. 2012;83:248-56 pubmed publisher |
Rimkunas V, Crosby K, Li D, Hu Y, Kelly M, Gu T, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-57 pubmed publisher |
